

## **Sex differences in adults with Attention-Deficit/Hyperactivity Disorder: A population-based study**

### *Sex differences in adults with ADHD*

Ferran Mestres <sup>1,†</sup>, Vanesa Richarte <sup>1,2,3,4,†</sup>, Juan Jesús Crespín <sup>1</sup>, Carla Torrent <sup>3,5,6</sup>, Santiago Biel <sup>1</sup>, Carolina Ramos <sup>2</sup>, Pol Ibáñez <sup>2</sup>, Laura Oltra-Arañó <sup>1</sup>, Montse Corrales <sup>1,2,3,4,\*</sup>, Silvia Amoretti <sup>2,3,\*</sup>, Christian Fadeuilhe <sup>1,2,3,4,¥</sup>, Josep Antoni Ramos-Quiroga <sup>1,2,3,4,¥</sup>

<sup>1</sup> Department of Psychiatry, Hospital Universitari Vall d'Hebron, Barcelona, Catalonia, Spain

<sup>2</sup> Group of Psychiatry, Mental Health and Addiction, Vall d'Hebron Research Institute (VHIR), Barcelona, Spain.

<sup>3</sup> Biomedical Network Research Centre on Mental Health (CIBERSAM), Barcelona, Catalonia, Spain

<sup>4</sup> Department of Psychiatry and Forensic Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain

<sup>5</sup> Bipolar and Depressive Disorders Unit, Hospital Clínic de Barcelona; Institut de Neurociències (UBNeuro); Fundació Clínic-Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS); CIBERSAM, ISCIII, Barcelona, Spain

<sup>6</sup> Departament de Medicina, Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona (UB), c. Casanova, 143, 08036 Barcelona, Spain.

† Joint first authors: Ferran Mestres and Vanesa Richarte

¥ Joint last authors: Christian Fadeuilhe and Josep Antoni Ramos-Quiroga

\*Corresponding authors:

Silvia Amoretti

*E-mail address:*

[silvia.amoretti@vhir.org](mailto:silvia.amoretti@vhir.org)

Montse Corrales

*E-mail address:*

[montserrat.corrales@vallhebron.cat](mailto:montserrat.corrales@vallhebron.cat)

Psychiatric Department. Hospital Universitari Vall d'Hebron.

Passeig Vall d'Hebron 119-129,

08035 Barcelona, Spain. Phone 0034 93 489 42 95 Fax 0034 93 489 45 87

This peer-reviewed article has been accepted for publication but not yet copyedited or typeset, and so may be subject to change during the production process. The article is considered published and may be cited using its DOI.

This is an Open Access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives licence (<http://creativecommons.org/licenses/by-nc-nd/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is unaltered and is properly cited. The written permission of Cambridge University Press must be obtained for commercial re-use or in order to create a derivative work.

## **Abstract**

### **BACKGROUND**

Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder that often persists into adulthood, significantly impacting daily functioning and quality of life. Sex differences influence ADHD presentation, with females experiencing delayed diagnosis and distinct patterns of severity and comorbidities. Exploring these differences is essential to improve diagnostic accuracy and tailored interventions. This study examines ADHD severity, psychiatric comorbidities, and functional impairment by ADHD subtype and sex, evaluating their interactions.

### **METHODS**

This population-based study included 900 adults diagnosed with ADHD. ADHD severity, psychiatric comorbidities, and functional outcomes were assessed using validated tools. Bivariate analyses and General Linear Models (GLM) were applied to examine sex- and subtype-specific effects and their interactions.

### **RESULTS**

Females exhibited greater ADHD severity ( $p < 0.001$ ), higher levels of depression ( $p = 0.003$ ) and anxiety ( $p < 0.001$ ), lower substance use ( $p < 0.001$ ), poorer psychosocial functioning ( $p = 0.039$ ), and greater disability ( $p = 0.001$ ) than males. No significant sex differences were found in ADHD subtype distribution or age of dysfunctional symptom onset; however, females were diagnosed with ADHD later than males ( $p < 0.001$ ). The combined ADHD subtype was associated with greater clinical severity, higher levels of depressive, anxiety, and impulsive symptoms, increased rates of substance use, and greater disability. A significant interaction effect between sex and ADHD subtype was observed only for disability, with females in the combined subtype exhibiting the most pronounced impairment.

### **CONCLUSIONS**

ADHD presents differently across sexes and subtypes, with specific interactions influencing disability. These findings emphasize the importance of considering sex and ADHD subtype independently to enhance diagnostic accuracy and develop more effective targeted treatment strategies.

**Keywords:** Attention-deficit/hyperactivity disorder (ADHD); Sex differences; Psychiatric comorbidities; Functional impairment; ADHD subtypes

## 1. Introduction

Attention-deficit/hyperactivity disorder (ADHD) is a well-known neurodevelopmental disorder that follows a clinical course through adulthood in most cases. More specifically, it is estimated that approximately two-thirds of children with ADHD will exhibit symptoms in adulthood [1]. Over the past decades, a rising prevalence of adolescent mental disorders, including ADHD and internalizing disorders, has been widely reported in the Western world [2], primarily driven by a major increase in ADHD diagnosed in adults. ADHD is relatively high in adults, with a pooled prevalence of ADHD in adults was 3.10% (95%CI 2.60–3.60%)[3]. ADHD is recognized by a clinical onset of inattention and/or hyperactivity-impulsivity symptoms, which have a remarkable impact in the life of the people who suffer from the disorder [4]. In this regard, although ADHD is considered a childhood disorder, over time the set of symptomatic manifestations becomes less specific and exhibits certain variations. To be more precise, in adulthood, inattentive symptoms are more prevalent and have a greater impact on the functionality of individuals compared to hyperactive symptoms which, in contrast, tend to cause greater impairment in children [5].

ADHD presents neurobiological, clinical, and etiological heterogeneity, which has posed a challenge in defining its diagnostic criteria over the years. To address this, the DSM-5 establishes three primary presentations of ADHD, which may vary over a person's lifespan and are classified as predominantly inattentive, predominantly hyperactive-impulsive, and combined [6]. Moreover, the combined presentation of ADHD, characterized by the presence of both inattentive and hyperactive-impulsive symptoms, is widely recognized as the subtype with the most severe clinical impairment. In particular, research indicates how the individuals affected by this subtype experience higher levels of comorbid conditions, greater behavioral disturbances, and poorer long-term outcomes [7]. Studies indicate that this ADHD subtype's impairments persist into adulthood, underscoring its chronic impact on quality of life and functionality [2]. Additionally, the combined presentation is associated with greater functional impairment

across academic, social, and occupational domains compared to other ADHD presentations [8].

Concerning sex differences, it has been considered that ADHD predominantly affects males over females [9]. More specifically, recent literature suggests that the prevalence may be approximately twice as high in boys compared to girls [10], with this difference narrowing in adulthood, where the male-to-female ratio is approximately 1.6:1 [11]. In relation to ADHD presentations, the inattentive presentation, which is less externalizing than other presentations, is suggested to be the primary cause of the underdiagnosis of ADHD in female individuals. In this sense, males, who predominantly exhibit the hyperactive and combined presentation of the disorder, tend to be more aggressive and disruptive in their close environment, leading to higher rates of seeking medical advice [12, 13]. In fact, females who exhibit higher levels of hyperactivity/impulsivity, also tend to present behavioral problems that facilitate early recognition of the disorder [14]. In addition to this symptomatic heterogeneity, cognitive functioning differences have also been observed between sex. Specifically, it has been found that while male individuals exhibit greater impulsivity and slower processing speed, female individuals show poorer outcomes in working memory and spatial reasoning [15, 16].

A recent population study has shown that the coexistence of a mental health disorder is extremely high, with approximately 80% of adult patients with ADHD estimated to have a comorbid mental health disorder [17, 18]. Several studies have shown increased severity of depression and anxiety in females, as well as lower self-esteem [19]. Specifically, females with ADHD who have been tracked into adulthood are 2.4 times more likely to be admitted to psychiatric facilities as adults compared to males with ADHD [20]. However, a notable percentage of cases of females seeking psychiatric care for a mood disorder might have undiagnosed ADHD. Indeed, in many cases, patients receive treatment for anxiety or depression while ADHD remains undiagnosed, leading to suboptimal therapeutic responses [21]. Nevertheless, when considering psychiatric comorbidity, it is known that certain disorders, such as substance use disorders, are

more common among men with ADHD than among women with ADHD [22]. Globally, individuals affected by ADHD are estimated to have higher mortality rates, with this increase being more pronounced in females compared to males [23].

This study aims to analyze the differences in the severity of the disorder, its comorbidity with other psychiatric diseases, and the socio-functional impact, depending on sex and ADHD subtype. Moreover, the interaction between ADHD presentation and sex in the outcomes obtained is examined. By addressing these aspects, this study seeks to enhance the understanding of ADHD and contribute to the development of more targeted management strategies and support tailored to diverse patient populations.

## **2. Material and methods**

### **2.1. Design of the study and participants**

This research was carried out within the adult ADHD Program at the Psychiatry Department of Vall d'Hebron University Hospital in Barcelona. The study received approval from the Clinical Research Ethics Committee of the Hospital Universitari Vall d'Hebron (PR(AG)103/2019). All participants voluntarily chose to take part in the study and did not receive any financial compensation.

The inclusion criteria required participants being over 18 years old, meeting the DSM-5 criteria for both ADHD and agreeing to and signing the informed consent form before participation. Exclusion criteria were IQ < 70, schizophrenia or other psychotic disorders, ADHD symptoms due to mood, anxiety, dissociative or personality disorders, adoption, sexual or physical abuse, birth weight <1.5 kg and other neurological or systemic disorders that might explain ADHD symptoms.

A total of 900 patients met the inclusion criteria (54,9% of whom were male, with a mean age of 36.94±11.93 years). The combined presentation of ADHD was the most prevalent subtype, present in 48.2% of the participants.

## **2.2. Instruments and Variables**

### **ADHD Diagnosis**

Patients with ADHD are characterized by alterations in various executive functions, with dysfunction reflected in different tests and scales. However, there is currently no test or combination of tests with sufficient positive predictive value to establish the diagnosis on an individual basis [24]. For this reason, in this study, we used the Conners' Adult ADHD Diagnostic Interview for DSM-IV (CAADID-I) and the Diagnostic Interview for ADHD in Adults, Fifth Edition (DIVA-5), two of the diagnostic tools that currently show the highest sensitivity and specificity for establishing the diagnosis of this disorder [25, 26].

These instruments, validated for in the Spanish population were used to assess and confirm ADHD diagnosis. They exhibit good psychometric properties in line with DSM-5 criteria [27, 28].

### **ADHD Severity**

The ADHD Rating Scale (ADHD-RS) was used to evaluate the clinical severity of ADHD. It is a self-administered 18-item scale that evaluates symptoms of attention deficit, hyperactivity, and impulsivity in adults with ADHD, providing a high sensitivity and specificity [29]. Also, the Wender Utah Rating Scale (WURS) and the Clinical Global Impression Severity Scale (CGI-S) were used to assess the severity of ADHD. Both tests are also a reliable tool for evaluating these parameters [30, 31].

### **Psychiatric Comorbidities and Psychological Characteristics**

To assess psychiatric comorbidities associated with ADHD, a series of scales and tests have been used.

Firstly, the Beck-II Depression Inventory II (BDI-II) was employed to assess depressive symptoms [32]. This instrument is of significant relevance, demonstrating strong psychometric properties [33]. In the second place, the State-Trait Anxiety Inventory (STAI) was used to evaluate anxiety in terms of both trait and state [34]. It is a widely used scale, with demonstrated accuracy in both clinical and research settings [35]. Furthermore, the Barratt Impulsiveness Scale (BIS-11) was employed to assess trait impulsivity. This scale measures impulsivity as a multidimensional concept (cognitive impulsivity, motor impulsivity, and unplanned impulsivity) with robust reliability [36].

Another aspect assessed among study participants was their sleep quality, evaluated using the Pittsburgh Sleep Quality Index (PSQI). This self-reported questionnaire comprises 19 items and measures seven key aspects of sleep: sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbance, use of sleeping medication, and daytime dysfunction [37]. Currently, the PSQI stands out as one of the main standardized clinical tools encompassing a comprehensive array of indicators pertinent to sleep quality [38].

Moreover, to discern the impact of ADHD on the psychosocial functioning of patients, we utilized The Functioning Assessment Short Test (FAST). This questionnaire, consisting of 24 items distributed across six functional categories, presents evidence that supports this tool's scientific validation and reliability in clinical practice, confirming its effectiveness in gathering comprehensive information on symptoms and functioning related to ADHD patient behavioral issues during interviews [39].

Furthermore, to assess the functional impact of the disorder, we used the World Health Organization Disability Assessment Schedule version 2.0 (WHODAS), a questionnaire that measures the individual's level of disability across six life domains: cognition, mobility, self-care, getting along, life activities, and participation in society [40]. This tool exhibits high internal consistency and robust psychometric properties for measuring

functional impairment in individuals with various health issues, including mental health disorders [41].

Finally, to ensure a rigorous diagnostic approach, the Structured Clinical Interview for DSM-IV Axis I and II Disorders (SCID-I and SCID-II) was conducted.

### **2.3. Procedure**

The Adult ADHD Program at the Hospital Universitari Vall d'Hebron is a multidisciplinary and comprehensive program that evaluates and treats patients referred from primary care centers, community mental health centers, and addiction treatment units. Upon referral to the ADHD Program, patients undergo a thorough assessment to establish their diagnosis and treatment plan.

For this study, the evaluation process involved five visits conducted by trained staff specializing in ADHD including psychiatrists and psychologists. During the initial visit, the psychiatrist conducted a comprehensive medical history, gathered pertinent sociodemographic data and obtained relevant information regarding the patient's ADHD clinical presentation. Alcohol and substance use were evaluated through a clinical interview conducted by trained clinicians. Participants were asked about their history of substance use, including the age of first use, age of last use, period of maximum consumption, and quantity of use. Standardized assessments using validated instruments for ADHD (CAADID-I, DIVA-5, CGI-S) were also performed. In three subsequent visits, the psychologist conducted evaluations using the following tests: WURS, ADHS-RS, BDI, STAI, BIS-11, PSQI, FAST, and WHODAS. During the fifth visit, the psychiatrist established the diagnosis of ADHD in accordance with the study results based on DSM-5 criteria. Additionally, to ensure a rigorous diagnostic approach, the Structured Clinical Interview for DSM-IV Axis I and II Disorders (SCID-I and SCID-II) was conducted. This structured interview allowed for the confirmation of the ADHD diagnosis and the exclusion of other psychiatric disorders. Finally, regardless of whether the patient



was diagnosed with ADHD, he was offered subsequent psychiatric and psychological treatment (either within our program or another unit) based on their clinical condition.

## **2.4. Statistical analyses**

Bivariate analyses were executed using SPSS version 26 for Windows. Initially, a comprehensive descriptive analysis of all variables was performed, including their percentages, means, and standard deviations.

Categorical variables were examined using the chi-square test, and the effect size was calculated using Cohen's *d* for continuous data or Cramér's *V* for nominal data. The interaction between sex and ADHD type was assessed for clinical, sociodemographic, and psychosocial functioning variables using a General Linear Model (GLM). All statistical hypotheses were tested using two-sided tests, with a *p*-value of less than 0.05 deemed statistically significant.

## **3. Results**

### **3.1. Sex-based differences in ADHD**

Sociodemographic, clinical and functional variables are presented in **Table 1**. Regarding sociodemographic characteristics, no significant differences were found between males and females, except for age and legal problems, since males were significantly younger than females ( $t=3.673$ ,  $p<0.001$ ) and had a higher incidence of legal problems ( $X^2=24.924$ ,  $p<0.001$ )

No significant differences were found in the age of onset of dysfunctional ADHD symptoms ( $p=0.220$ ). However, a later age of ADHD diagnosis was observed in females ( $28.96\pm14.75$  years vs.  $24.13\pm15.12$  years,  $t=3.540$ ,  $p<0.001$ ) (see **Figure 1**).

Regarding the severity of ADHD, females exhibited higher scores on the ADHD-RS ( $t=4.009$ ,  $p<0.001$ ). Expectedly, female patients with ADHD were more likely to exhibit higher levels of depression and anxiety than male patients, as reflected by their higher scores on the BDI ( $p=0.003$ ) and STAI scales (trait,  $p=0.010$ ; state,  $p<0.001$ ). However,

no statistically significant differences were observed between females and males in terms of impulsivity and insomnia. The females included in the study also exhibited greater impairment in psychosocial functioning and disability, obtaining higher scores on the FAST ( $t=2.064$ ,  $p=0.039$ ) and WHODAS ( $t=3.287$ ,  $p=0.001$ ) tests compared to the males.

Finally, males exhibited higher rates of substance use compared to females. Specifically, alcohol use was reported by a greater percentage of males (39.4%) than females (28.2%) ( $X^2=12.364$ ,  $p<0.001$ ). Similarly, tobacco use was more prevalent among males (32.7%) than females (26.6%) ( $X^2=4.024$ ,  $p=0.026$ ). Cannabis use followed this pattern, with 22.6% of males reporting use compared to 12.9% of females ( $X^2=13.872$ ,  $p<0.001$ ).

*[Please insert Table 1 and Figure 1 here]*

### 3.2. Differences Across ADHD Subtypes

**Table 2** presents an analysis of the sociodemographic and clinical characteristics of the patients included in the study based on their ADHD subtype. A higher proportion of participants with the inattentive subtype were working or studying (82.6%) compared to those with the combined subtype (77.7%,  $p=0.042$ ). Patients with the combined subtype reported more legal problems (17.7% vs. 8.6%,  $p<0.001$ ).

Results indicate that patients with a combined presentation of ADHD exhibited a higher severity of the disorder (as measured by the WURS, ADHD-RS, and CGI scales) compared to those with the inattentive presentation. Additionally, patients with the combined subtype reported significantly higher levels of depression (BDI), anxiety (STAI), and impulsivity (BIS-11), while no differences were observed in sleep quality (PSQI). Participants diagnosed with the combined presentation of the disorder reported higher levels of disability (WHODAS) compared to those with the inattentive presentation; however, no significant differences were observed in psychosocial

functioning (FAST) between the two groups.

Finally, substance use patterns also differed between subtypes. Participants with the combined presentation showed higher rates of alcohol consumption (39.4% vs. 29.7%,  $p=0.002$ ), tobacco use (35.3% vs. 25.0%,  $p=0.001$ ), and cannabis use (24.6% vs. 12.3%,  $p<0.001$ ) compared to those with the inattentive subtype.

*[Please insert Table 2 here]*

### 3.3. Interaction between sex and ADHD subtypes

Despite observing differences in symptom severity and functional impairment depending on sex or ADHD subtype, the interaction between sex and ADHD subtype did not significantly influence these outcomes (**Table 3**), except for disability (WHODAS,  $p=0.015$ ) (**Figure 2**). Specifically, females with the combined ADHD subtype exhibited greater disability compared to both males with the same subtype and individuals of either sex with the inattentive subtype.

*[Please insert Table 3 and Figure 2 here]*

## 4. Discussion

The current study provides new insights into the clinical severity of ADHD and its impact, with a focus on differences between males and females and ADHD subtype.

One of the most significant findings in the studied sample is the later age at which ADHD is diagnosed in females compared to males. This finding is consistent with the fact that male individuals more frequently present the hyperactive/impulsive variant of the disorder and are thus more likely to be referred to a specialist at an earlier age, allowing for earlier recognition of the disorder [42]. Conversely, and in line with findings from other studies, female individuals diagnosed with ADHD exhibit greater clinical severity of the disorder. This may be related to the higher likelihood of missed or delayed diagnosis in

women, which ultimately leads to a greater impact of the disorder in affected females [16].

Congruent with a recently published meta-analysis [43], female individuals were found to be more affected by anxiety and depression than male individuals. However, this relationship does not extend to other disorders examined, as our results indicate that sex does not significantly influence the risk of increased impulsivity or poorer sleep quality. Regarding psychosocial functioning impairment, our findings align with current evidence, showing greater difficulties in females. These results may suggest that late detection of the disorder, higher psychiatric comorbidity, and delays in initiating accurate treatment for female patients with ADHD contribute to greater social difficulties and feelings of rejection by peers from an early age [44, 45]. Furthermore, this study along with recent literature has demonstrated that adult males with ADHD present a higher prevalence of other psychiatric disorders, such as substance use disorders or disruptive behavior disorders, compared to adult females [46].

When examining the severity of ADHD based on subtype, we found that individuals with the combined presentation scored higher on the WURS scale, which measures the intensity of symptoms reported in childhood, and on the ADHD-RS scale, which evaluates current symptomatology. These findings are consistent with a German study that also utilized the WURS scale and reported higher scores for individuals with the combined subtype [47]. The greater clinical impact of the combined presentation is likely attributable to the higher prevalence of disruptive behaviors and psychiatric comorbidities associated with this subtype, as highlighted by a Chinese study [48]. Regarding functional outcomes, our findings indicate that individuals with the combined presentation exhibit significantly greater levels of disability (WHODAS), but no differences were observed in psychosocial functioning (FAST). The combined subtype's higher rates of impulsivity, substance use, and legal problems may exacerbate perceived disability across multiple life domains, which could explain the observed differences in

WHODAS scores. Supporting this, an Italian study [49] reported that individuals with the combined presentation exhibit greater deterioration in personal relationships, likely driven by impulsive and inappropriate behaviors. The differences observed between ADHD subtypes in WHODAS scores but not in FAST scores could be attributed to the differences in how these scales capture functional impairments. The WHODAS 2.0 provides a broader overview of disability, capturing the overall impact of functional impairments across multiple life domains. This may be particularly relevant for individuals experiencing impulsivity-driven disruptions or external consequences, such as legal issues. In contrast, the FAST offers a more focused assessment of specific areas of daily functioning, such as autonomy, work, interpersonal relationships, and leisure [50].

The lack of a significant interaction between sex and ADHD subtype for most clinical and functional outcomes suggests that, while there are clear differences in symptom severity and functional impairment based on sex and ADHD subtype, these factors largely operate independently. In other words, both male and female participants exhibit similar patterns of symptom severity within each ADHD subtype. However, it is important to note that females with the combined ADHD subtype demonstrated greater disability (WHODAS) compared to males with the same subtype and individuals of either sex with the inattentive subtype. This finding indicates that, although sex does not broadly influence symptom severity within ADHD subtypes, it plays a specific role in modulating disability in individuals with the combined presentation. These results highlight the importance of considering both sex and ADHD subtype independently when assessing and treating individuals with ADHD. Several factors may contribute to this observed disparity in disability among females with the combined subtype. Biologically, hormonal fluctuations, particularly estrogen's influence on dopamine regulation, may impact emotional regulation, stress response, and executive functions in ADHD [51]. Given that executive function and emotional regulation are crucial for managing daily life demands, hormonal effects may exacerbate disability in females with the combined subtype.

Psychosocial factors also play a role, as women with ADHD often face greater societal expectations related to organization, multitasking, and emotional regulation, leading to increased perceived impairment when these expectations are not met [16]. Additionally, females with ADHD are diagnosed later than males, often after prolonged struggles with unrecognized symptoms [19]. The cumulative effect of delayed diagnosis and inadequate intervention may contribute to increased disability scores. Furthermore, coping mechanisms differ by sex; while males with ADHD are more likely to externalize symptoms through impulsivity and risk-taking behaviors, females tend to develop compensatory mechanisms such as excessive self-monitoring and emotional suppression. Although these strategies may help mask symptoms in the short term, they often result in chronic stress and emotional exhaustion, further contributing to higher disability scores [16, 19]. These findings highlight the importance of incorporating disability measures in ADHD assessments, particularly for females, as symptom severity scales alone may not adequately capture the full extent of the disorder's impact on daily functioning and quality of life.

The study has several limitations that should be considered. First, the sample was drawn from a clinical setting, which may not fully represent the broader population of individuals with ADHD. This could introduce selection bias and limit the generalizability of the findings. Second, the cross-sectional design of the study precludes causal inferences between ADHD subtype, sex, and the observed clinical and functional outcomes. Longitudinal studies are needed to explore the temporal relationships between these factors. Despite these limitations, the study has notable strengths. The inclusion of a diverse cohort of participants from a specialized ADHD clinic enables a more comprehensive analysis of the disorder across different subtypes and sexes. Additionally, the large sample size enhances the statistical power and reliability of the findings. Furthermore, the use of multiple validated instruments to assess ADHD severity, psychiatric comorbidities, and functional impairment ensures a robust,

multidimensional evaluation of the disorder's impact on individuals.

In conclusion, this study underscores the complexity of ADHD as a multifaceted disorder influenced by both sex and ADHD subtype. While our findings indicate that sex does not broadly influence the relationship between ADHD subtype and symptom severity, it may have a more nuanced impact on specific aspects of disability, particularly in females with the combined presentation. These insights are crucial for improving diagnostic accuracy and developing more tailored treatment strategies. Future research should continue to explore these dimensions, considering how other variables, such as age, socioeconomic status, comorbid conditions, sociocultural differences and biological conditions specific to the female sex, such as the regulation of hormonal cycles, might interact with sex and subtype to influence ADHD outcomes.

## **Funding**

The funding sources had no role in the design and conducting of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

## **Acknowledgments**

We are extremely grateful to all participants.

Dr. Amoretti has been supported by Sara Borrell doctoral programme (CD20/00177) and M-AES mobility fellowship (MV22/00002), from the Instituto de Salud Carlos III (ISCIII), and co-funded by European Social Fund “Investing in your future” and La Marató-TV3 Foundation grants 202234-32.

Dr. Amoretti (PI24/00671) and Dr. Torrent (PI20/00344; PI24/00407) thank the support of the Spanish Ministry of Innovation and Science, funded by the Instituto de Salud Carlos III and cofinanced by the European Union (FEDER) “Una manera de hacer Europa”.

## **Conflicts of interest**

Dr. Vanesa Richarte declares that she has given lectures or received help to attend conferences from Rubió and Shire/Takeda. Dr. Christian Fadeuilhe declares that he has given lectures or received help to attend conferences from Rubió and Shire/Takeda. Dr. Montse Corrales declares that she has received help to attend conferences from Shire/Takeda. Dr. Silvia Amoretti has been a consultant to and/or has received honoraria/grants from Otsuka-Lundbeck, with no financial or other relationship relevant to the subject of this article. Professor Josep Antoni Ramos-Quiroga was part of the



speakers' bureau and/or acted as a consultant for Eli-Lilly, Janssen-Cilag, Novartis, Shire, Takeda, Bial, Shionogui, Lundbeck, Almirall, Braingaze, Sincrolab, Medice and Rubió in the last 5 years. He has also received help to attend conferences from Janssen-Cilag, Rubió, Shire, Takeda, Shionogui, Bial, Medice and Eli-Lilly.

All other authors report no financial or other relationship relevant to the subject of this article.

### **Ethics statement**

The study was approved by the Clinical Research Ethics Committee of the Vall d'Hebron University Hospital. The study participants have provided written informed consent for their participation in the study.

### **Data Availability Statement**

The data that support the findings of this study are available on request from the corresponding authors.

## References

- [1] Caye A, Rocha TB-M, Anselmi L, Murray J, Menezes AMB, Barros FC, et al. Attention-deficit/hyperactivity disorder trajectories from childhood to young adulthood: evidence from a birth cohort supporting a late-onset syndrome. *JAMA Psychiatry*. 2016;73:705-12. Medline:27192050 doi:10.1001/jamapsychiatry.2016.0383.
- [2] Nordmo M, Kleppestø TH, Reme BA, Sunde HF, von Soest T, Torvik FA. The diminishing association between adolescent mental disorders and educational performance from 2006-2019. *JCPP Adv*. 2024 May 31;4(3):e12239. doi: 10.1002/jcv2.12239.
- [3] Ayano G, Tsegay L, Gizachew Y, Necho M, Yohannes K, Abraha M, Demelash S, Anbesaw T, Alati R. Prevalence of attention deficit hyperactivity disorder in adults: Umbrella review of evidence generated across the globe. *Psychiatry Res*. 2023 Oct;328:115449. doi: 10.1016/j.psychres.2023.115449
- [4] Faraone SV, Asherson P, Banaschewski T, Biederman J, Buitelaar JK, Ramos-Quiroga JA, Rohde LA, Sonuga-Barke EJ, Tannock R, Franke B. Attention-deficit/hyperactivity disorder. *Nat Rev Dis Primers*. 2015;1:15020. doi: 10.1038/nrdp.2015.20.
- [5] Das D, Cherbuin N, Butterworth P, Anstey KJ, Easteal S. A population-based study of attention deficit/hyperactivity disorder symptoms and associated impairment in middle-aged adults. *PLoS One*. 2012;7(2):e31500. doi: 10.1371/journal.pone.0031500.
- [6] Nigg JT, Tannock R, Rohde LA. What is to be the fate of ADHD subtypes? An introduction to the special section on research on the ADHD subtypes and implications for the DSM-V. *J Clin Child Adolesc Psychol*. 2010;39(6):723-5. doi: 10.1080/15374416.2010.517171.
- [7] Mowlem FD, Rosenqvist MA, Martin J, Lichtenstein P, Asherson P, Larsson H. Sex differences in predicting ADHD clinical diagnosis and pharmacological treatment.

- Eur Child Adolesc Psychiatry. 2019;28(4):481-489. doi: 10.1007/s00787-018-1211-3.
- [8] Holst Y, Thorell LB. Functional impairments among adults with ADHD: A comparison with adults with other psychiatric disorders and links to executive deficits. *Appl Neuropsychol Adult*. 2020;27(3):243-255. doi: 10.1080/23279095.2018.1532429.
- [9] Skounti M, Philalithis A, Galanakis E. Variations in prevalence of attention deficit hyperactivity disorder worldwide. *Eur J Pediatr*. 2007;166(2):117-23. doi: 10.1007/s00431-006-0299-5.
- [10] Ayano G, Demelash S, Gizachew Y, Tsegay L, Alati R. The global prevalence of attention deficit hyperactivity disorder in children and adolescents: An umbrella review of meta-analyses. *J Affect Disord*. 2023;339:860-866. doi: 10.1016/j.jad.2023.07.071.
- [11] Willcutt EG. The prevalence of DSM-IV attention-deficit/hyperactivity disorder: a meta-analytic review. *Neurotherapeutics*. 2012;9(3):490-9. doi: 10.1007/s13311-012-0135-8.
- [12] Hinshaw SP, Nguyen PT, O'Grady SM, Rosenthal EA. Annual Research Review: Attention-deficit/hyperactivity disorder in girls and women: underrepresentation, longitudinal processes, and key directions. *J Child Psychol Psychiatry*. 2022;63(4):484-496. doi: 10.1111/jcpp.13480.
- [13] Waite R. Women with ADHD: it is an explanation, not the excuse du jour. *Perspect Psychiatr Care*. 2010;46(3):182-96. doi: 10.1111/j.1744-6163.2010.00254.x.
- [14] Biederman J, Faraone SV, Mick E, Williamson S, Wilens TE, Spencer TJ, Weber W, Jetton J, Kraus I, Pert J, Zallen B. Clinical correlates of ADHD in females: findings from a large group of girls ascertained from pediatric and psychiatric referral sources. *J Am Acad Child Adolesc Psychiatry*. 1999;38(8):966-75. doi: 10.1097/00004583-199908000-00012.

- [15] Nussbaum NL. ADHD and female specific concerns: a review of the literature and clinical implications. *J Atten Disord.* 2012;16(2):87-100. doi: 10.1177/1087054711416909.
- [16] Rucklidge JJ. Gender differences in attention-deficit/hyperactivity disorder. *Psychiatr Clin North Am.* 2010;33(2):357-73. doi: 10.1016/j.psc.2010.01.006.
- [17] Seo J-C, Jon D-I, Shim S-H, Sung H-M, Woo YS, Hong J, et al. Prevalence and Comorbidities of Attention Deficit Hyperactivity Disorder Among Adults and Children/Adolescents in Korea. *Clin Psychopharmacol Neurosci.* 2022;20(1):126–34.
- [18] Stickley A, Koyanagi A, Takahashi H, Ruchkin V, Inoue Y, Kamio Y. Attention-deficit/hyperactivity disorder and physical multimorbidity: population-based study. *Eur Psychiatry.* 2017 Sep;45:227-234. doi: 10.1016/j.eurpsy.2017.07.010.
- [19] Gershon J. A meta-analytic review of gender differences in ADHD. *J Atten Disord* 2002;5(3):143–54.
- [20] Dalsgaard S, Mortensen PB, Frydenberg M, Thomsen PH. Conduct problems, gender and adult psychiatric outcome of children with attention-deficit hyperactivity disorder. *Br J Psychiatry.* 2002 Nov;181:416-21. doi: 10.1192/bjp.181.5.416.
- [21] Quinn PO, Madhoo M. A review of attention-deficit/hyperactivity disorder in women and girls: uncovering this hidden diagnosis. *Prim Care Companion CNS Disord.* 2014;16(3):PCC.13r01596. doi: 10.4088/PCC.13r01596.
- [22] Solberg BS, Halmøy A, Engeland A, Igland J, Haavik J, Klungsøyr K. Gender differences in psychiatric comorbidity: a population-based study of 40 000 adults with attention deficit hyperactivity disorder. *Acta Psychiatr Scand.* 2018 Mar;137(3):176-186. doi: 10.1111/acps.12845.
- [23] Dalsgaard S, Østergaard SD, Leckman JF, Mortensen PB, Pedersen MG. Mortality in children, adolescents, and adults with attention deficit hyperactivity disorder: a nationwide cohort study. *Lancet.* 2015 May 30;385(9983):2190-6. doi: 10.1016/S0140-6736(14)61684-6.

- [24] Wasserman T, Wasserman LD. The sensitivity and specificity of neuropsychological tests in the diagnosis of attention deficit hyperactivity disorder. *Appl Neuropsychol Child*. 2012;1(2):90-9. doi: 10.1080/21622965.2012.702025.
- [25] Pettersson R, Söderström S, Nilsson KW. Diagnosing ADHD in Adults: An Examination of the Discriminative Validity of Neuropsychological Tests and Diagnostic Assessment Instruments. *J Atten Disord*. 2018 Sep;22(11):1019-1031. doi: 10.1177/1087054715618788.
- [26] Erhardt D, Epstein JN, Conners CK, Parker JDA, Sitarenios G. Self-ratings of ADHD symptoms in adults II: reliability, validity, and diagnostic sensitivity. *J Atten Disord*. (1999) 3:153–8. doi: 10.1177/108705479900300304.
- [27] Ramos-Quiroga JA, Bosch R, Richarte V, Valero S, Gómez-Barros N, Nogueira M, Palomar G, Corrales M, Sáez-Francàs N, Corominas M, Real A, Vidal R, Chalita PJ, Casas M. Criterion and concurrent validity of Conners Adult ADHD Diagnostic Interview for DSM-IV (CAADID) Spanish version. *Rev Psiquiatr Salud Ment*. 2012 Oct-Dec;5(4):229-35. English, Spanish. doi: 10.1016/j.rpsm.2012.05.004.
- [28] Ramos-Quiroga JA, Nasillo V, Richarte V, Corrales M, Palma F, Ibáñez P, Michelsen M, Van de Glind G, Casas M, Kooij JJS. Criteria and Concurrent Validity of DIVA 2.0: A Semi-Structured Diagnostic Interview for Adult ADHD. *J Atten Disord*. 2019;23(10):1126-1135. doi: 10.1177/1087054716646451.
- [29] Pereira A, Richarte V, Fadeuilhe C, Corrales M, García E, Ramos-Quiroga JA. ADHD Rating Scale (ADHD-RS): Validation in Spanish in adult population according to the DSM-5. *Span J Psychiatry Ment Health*. 2024 Jan-Mar;17(1):46-50. doi: 10.1016/j.sjpmh.2023.06.002.
- [30] Brevik EJ, Lundervold AJ, Haavik J, Posserud MB. Validity and accuracy of the Adult Attention-Deficit/Hyperactivity Disorder (ADHD) Self-Report Scale (ASRS) and the Wender Utah Rating Scale (WURS) symptom checklists in discriminating between adults with and without ADHD. *Brain Behav*. 2020 Jun;10(6):e01605. doi: 10.1002/brb3.1605.


- [31] Guy, W., 1976. ECDEU assessment manual for psychopharmacology. US Department of Health, Education, and Welfare, Public Health Service Service Alcohol, Drug Abuse, and Mental Health Administration.
- [32] Beck AT, Steer RA, Brown GK. Manual for the Beck Depression Inventory-II. San Antonio: TX Psychol Corp. (1996).
- [33] Wang YP, Gorenstein C. Psychometric properties of the Beck Depression Inventory-II: a comprehensive review. *Braz J Psychiatry*. 2013 Oct-Dec;35(4):416-31. doi: 10.1590/1516-4446-2012-1048.
- [34] Spielberg CD, Gorsuch RL, Lushene RE. Manual for the State-Trait Inventory. Palo Alto: Consult Psychol Press (1970).
- [35] Guillén-Riquelme A, Buela-Casal G. Actualización psicométrica y funcionamiento diferencial de los ítems en el state trait anxiety inventory (STAI). *Psicothema*. (2011) 23:510–5.
- [36] Patton JH, Stanford MS, Barratt ES. Factor structure of the Barratt impulsiveness scale. *J Clin Psychol*. 1995 Nov;51(6):768-74. doi: 10.1002/1097-4679(199511)51:6<768::aid-jclp2270510607>3.0.co;2-1.
- [37] Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh sleep quality index: a new instrument for psychiatric practice and research. *Psychiatry Res*. (1989) 28:193–213. doi: 10.1016/0165-1781(89)90047-4
- [38] Mollaveva T, Thurairajah P, Burton K, Mollaveva S, Shapiro CM, Colantonio A. The Pittsburgh sleep quality index as a screening tool for sleep dysfunction in clinical and non-clinical samples: A systematic review and meta-analysis. *Sleep Med Rev*. 2016 Feb;25:52-73. doi: 10.1016/j.smrv.2015.01.009.
- [39] Rotger S, Richarte V, Nogueira M, Corrales M, Bosch R, Vidal R, Marfil L, Valero S, Vieta E, Goikolea JM, Torres I, Rosa A, Mur M, Casas M, Ramos-Quiroga JA. Functioning Assessment Short Test (FAST): validity and reliability in adults with attention-deficit/hyperactivity disorder. *Eur Arch Psychiatry Clin Neurosci*. 2014 Dec;264(8):719-27. doi: 10.1007/s00406-014-0501-0.

- [40] Ustün TB, Chatterji S, Kostanjsek N, Rehm J, Kennedy C, Epping-Jordan J, Saxena S, von Korf M, Pull C; WHO/NIH Joint Project. Developing the World Health Organization Disability Assessment Schedule 2.0. *Bull World Health Organ*. 2010 Nov 1;88(11):815-23. doi: 10.2471/BLT.09.067231.
- [41] Konecky B, Meyer EC, Marx BP, Kimbrel NA, Morissette SB. Using the WHODAS 2.0 to assess functional disability associated with DSM-5 mental disorders. *Am J Psychiatry*. 2014 Aug;171(8):818-20. doi: 10.1176/appi.ajp.2014.14050587.
- [42] Skoglund C, Sundström Poromaa I, Leksell D, Ekholm Selling K, Cars T, Giacobini M, Young S, Kopp Kallner H. Time after time: failure to identify and support females with ADHD - a Swedish population register study. *J Child Psychol Psychiatry*. 2024 Jun;65(6):832-844. doi: 10.1111/jcpp.13920.
- [43] Faheem M, Akram W, Akram H, Khan MA, Siddiqui FA, Majeed I. Gender-based differences in prevalence and effects of ADHD in adults: A systematic review. *Asian J Psychiatr*. 2022 Sep;75:103205. doi: 10.1016/j.ajp.2022.103205.
- [44] Lynn N. M. (2019). Women & ADHD functional impairments: beyond the obvious [Master's thesis, Grand Valley State University]. Graduate Research and Creative Practice at Scholar Works
- [45] Stenner P., O'Dell L., Davies A. (2019). Adult women and ADHD: On the temporal dimensions of ADHD identities. *Journal for the Theory of Social Behaviour*, 49, 179–197. 10.1111/jtsb.12198
- [46] McGillivray JA, Baker KL. Effects of comorbid ADHD with learning disabilities on anxiety, depression, and aggression in adults. *J Atten Disord*. 2009 May;12(6):525-31. doi: 10.1177/1087054708320438.
- [47] Retz-Junginger P, Rösler M, Giesen LK, Philipp-Wiegmann F, Römer K, Zinnow T, Retz W. Der Einfluss des ADHS-Subtyps auf den Leidensdruck bei erwachsenen ADHS-Patienten [ADHD: Burden of Disease According to Subtypes in Adult Patients]. *Psychiatr Prax*. 2016 Jul;43(5):279-82. German. doi: 10.1055/s-0035-1552699.


- [48] Tsai FJ, Tseng WL, Yang LK, Gau SS. Psychiatric comorbid patterns in adults with attention-deficit hyperactivity disorder: Treatment effect and subtypes. *PLoS One*. 2019 Feb 7;14(2):e0211873. doi: 10.1371/journal.pone.0211873.
- [49] Salvi V, Migliarese G, Venturi V, Rossi F, Torriero S, Viganò V, Cerveri G, Mencacci C. ADHD in adults: clinical subtypes and associated characteristics. *Riv Psichiatr*. 2019 Mar-Apr;54(2):84-89. doi: 10.1708/3142.31249.
- [50] Gspandl S, Peirson RP, Nahhas RW, Skale TG, Lehrer DS. Comparing Global Assessment of Functioning (GAF) and World Health Organization Disability Assessment Schedule (WHODAS) 2.0 in schizophrenia. *Psychiatry Res*. 2018 Jan;259:251-253. doi: 10.1016/j.psychres.2017.10.033.
- [51] Eng AG, Nirjar U, Elkins AR, Sizemore YJ, Monticello KN, Petersen MK, Miller SA, Barone J, Eisenlohr-Moul TA, Martel MM. Attention-deficit/hyperactivity disorder and the menstrual cycle: Theory and evidence. *Horm Behav*. 2024 Feb;158:105466. doi: 10.1016/j.yhbeh.2023.105466



**Figure 1.** Age of onset of dysfunctional ADHD symptoms and diagnosis by sex



**Figure 2.** Interaction between sex and subtype of ADHD on functional impact as measured by the WHODAS scale.



**Table 1.** Clinical and sociodemographic characteristics of ADHD patients included in the study according to sex

	Females (n=406)	Males (n=494)	t o $\chi^2$	p	Effect size
<b>Sociodemographic features</b>					
Age	39.92±12.27	36.94±11.93	3.673	<b>&lt;0.001</b>	0.246
Marital status (single)	236 (62.1)	315 (67.2)	5.632	0.060	0.081
Coexistence (family)	317 (83.9)	385 (82.6)	3.018	0.221	0.060
Completed secondary education	63 (16.5)	99 (20.8)	5.001	0.082	0.076
Working/studying	300 (80)	375 (80.4)	1.842	0.765	0.047
Legal Problems: yes (%)	25 (6.6)	84 (18.1)	24.924	<b>&lt;0.001</b>	0.172
<b>Clinical characteristics</b>					
ADHD (combined type)	195 (48.0)	239 (48.4)	0.011	0.485	0.003
Age of onset of dysfunctional ADHD symptoms	14.49±12.17	12.53±11.42	1.229	0.220	0.166
Age of ADHD diagnosis	28.96±14.75	24.13±15.12	3.540	<b>&lt;0.001</b>	0.323
WURS	54.33±21.86	53.06±22.68	0.814	0.416	0.057
ADHD-RS	31.38±8.26	29.16±8.24	4.009	<b>&lt;0.001</b>	0.269
CGI	4.05±0.77	3.97±0.79	1.288	0.198	0.103
Depressive symptoms (BDI)	18.61±11.09	16.34±10.92	2.982	<b>0.003</b>	0.206
Anxiety trait (STAI)	31.30±13.05	28.94±13.25	2.586	<b>0.010</b>	0.179
Anxiety state (STAI)	35.93±11.34	32.50±11.35	4.341	<b>&lt;0.001</b>	0.302
Impulsivity (BIS-11)	69.57±14.72	68.75±16.06	0.761	0.447	0.053
Sleepiness scale (PSQI)	8.42±4.87	8.14±5.32	0.604	0.546	0.055
FAST	27.45±10.82	25.78±11.70	2.064	<b>0.039</b>	0.148
WHODAS	31.51±10.72	28.91±10.10	3.287	<b>0.001</b>	0.538
<b>Substance use</b>					
Alcohol	114 (28.2)	194 (39.4)	12.364	<b>&lt;0.001</b>	0.117
Tobacco	107 (26.6)	161 (32.7)	4.024	<b>0.026</b>	0.067
Cannabis	52 (12.9)	111 (22.6)	13.872	<b>&lt;0.001</b>	0.124

Abbreviations: WURS: Wender Utah Rating Scale; ADHD-RS: ADHD Rating Scale; CGI: Clinical Global Impression Scale; BDI: Beck-II Depression Inventory II; STAI: State-Trait Anxiety Inventory; BIS-11: Barratt Impulsiveness Scale; PSQI: Pittsburgh Sleep Quality Index; FAST: Functioning Assessment Short Test; WHODAS: World Health Organization Disability Assessment Schedule 2.0. Significant differences ( $p<0.05$ ) marked in bold.

**Table 2.** Clinical and sociodemographic characteristics of ADHD patients included in the study according to ADHD type

	<b>Combined ADHD (n=434)</b>	<b>Inattentive ADHD (n=466)</b>	<b>t o <math>\chi^2</math></b>	<b>p</b>	<b>Effect size</b>
<b>Sociodemographic features</b>					
Age	39.57±12.08	37.02±12.15	3.166	<b>0.002</b>	0.210
Sex (females)	195 (44.9)	211 (45.3)	0.011	0.485	0.003
Marital status (single)	250 (61.7)	301 (67.8)	3.680	0.159	0.066
Coexistence (family)	328 (81.2)	374 (85)	2.331	0.312	0.053
Completed secondary education	81 (19.9)	81 (18)	5.574	0.062	0.081
Working/studying	313 (77.7)	362 (82.6)	3.287	<b>0.042</b>	0.063
Legal Problems: yes (%)	71 (17.7)	38 (8.6)	5.380	<b>&lt;0.001</b>	0.153
<b>Clinical characteristics</b>					
Age of onset of dysfunctional ADHD symptoms	13.41±12.61	13.56±10.80	-0.092	0.927	0.013
Age of ADHD diagnosis	26.18±15.32	25.95±15.03	0.165	0.869	0.015
WURS	57.36±23.65	49.95±20.28	4.842	<b>&lt;0.001</b>	0.336
ADHD-RS	32.20±8.20	28.13±7.97	7.542	<b>&lt;0.001</b>	0.503
CGI	4.18±0.77	3.85±0.76	5.658	<b>&lt;0.001</b>	0.431
Depressive symptoms (BDI)	18.40±11.24	16.42±10.74	2.624	<b>0.009</b>	0.180
Anxiety trait (STAI)	31.42±13.30	28.65±12.95	3.061	<b>0.002</b>	0.211
Anxiety state (STAI)	35.11±11.72	33.01±11.14	2.656	<b>0.008</b>	0.184
Impulsivity (BIS-11)	73.24±14.10	65.02±15.64	7.968	<b>&lt;0.001</b>	0.552
Sleepiness scale (PSQI)	8.28±5.47	8.28±4.81	-0.004	0.997	0
FAST	26.97±11.62	26.07±11.00	1.116	0.265	0.080
WHODAS	31.28±10.77	28.92±10.00	3.009	<b>0.003</b>	0.227
<b>Substance use</b>					
Alcohol	170 (39.4)	138 (29.7)	9.456	<b>0.002</b>	0.103
Tobacco	152 (35.3)	116 (25.0)	11.228	<b>0.001</b>	0.112
Cannabis	106 (24.6)	57 (12.3)	22.730	<b>&lt;0.001</b>	0.159

Abbreviations: WURS: Wender Utah Rating Scale; ADHD-RS: ADHD Rating Scale; CGI: Clinical Global Impression Scale; BDI: Beck-II Depression Inventory II; STAI: State-Trait Anxiety Inventory; BIS-11: Barratt Impulsiveness Scale; PSQI: Pittsburgh Sleep Quality Index; FAST: Functioning Assessment Short Test; WHODAS: World Health Organization Disability Assessment Schedule 2.0. Significant differences ( $p<0.05$ ) marked in bold.

1 **Table 3.** Clinical characteristics according ADHD subtype and sex  
2

	Combined ADHD (n=434)		Inattentive ADHD (n=466)		Sex * ADHD type	
	Females	Males	Females	Males	X <sup>2</sup>	p
<b>Clinical characteristics</b>						
Age of onset of dysfunctional ADHD symptoms	13.20±1.51	13.62±1.49	16.17±1.72	11.25±1.62	2.84	0.092
Age of ADHD diagnosis	29.40±1.65	24.22±1.29	28.65±1.38	24.06±1.15	0.05	0.831
WURS	59.44±1.65	55.85±1.49	49.52±1.60	50.45±1.43	2.15	0.143
ADHD-RS	33.73±0.58	31.08±0.52	29.25±0.55	27.33±0.50	0.46	0.495
CGI	4.18±0.06	4.19±0.06	3.93±0.06	3.78±0.06	1.60	0.205
Depressive symptoms (BDI)	19.79±0.80	17.18±0.73	17.48±0.78	15.54±0.71	0.20	0.653
Anxiety trait (STAI)	32.98±0.96	30.05±0.88	29.67±0.94	27.88±0.85	0.40	0.530
Anxiety state (STAI)	37.45±0.83	33.25±0.76	34.48±0.81	31.78±0.74	0.89	0.346
Impulsivity (BIS-11)	74.02±1.10	72.81±1.01	65.41±1.07	64.89±0.98	0.11	0.740
Sleepiness scale (PSQI)	7.96±0.55	8.50±0.48	8.73±0.45	7.85±0.43	2.19	0.139
FAST	28.33±0.86	25.89±0.79	26.65±0.82	25.68±0.76	0.84	0.361
WHODAS	33.77±0.82	29.22±0.75	29.34±0.80	28.61±0.75	5.97	<b>0.015</b>

3 Abbreviations: WURS: Wender Utah Rating Scale; ADHD-RS: ADHD Rating Scale; CGI: Clinical Global  
4 Impression Scale; BDI: Beck-II Depression Inventory II; STAI: State-Trait Anxiety Inventory; BIS-11: Barratt  
5 Impulsiveness Scale; PSQI: Pittsburgh Sleep Quality Index; FAST: Functioning Assessment Short Test;  
6 WHODAS: World Health Organization Disability Assessment Schedule 2.0. Significant interactions (p<0.05)  
7 marked in bold.

8  
9  
10